SITC – the morning after the night before
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Flush with cash, Allogene tackles the production conundrum
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
SITC 2018 – The search for immuno-oncology combos continues
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
Allogene spells out its interest in Cellectis
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
